Setup News Ticker
Searching for 'shares INC'. (Return)

MarketWatch MarketPulseNov 20, 2019
Planet Fitness borrows $550 million and says it may use part of funds to reward shareholders
Planet Fitness Inc. said Wednesday it has priced a $550 million securitized financing and may use some of the proceeds to reward its own shareholders. The Hampton, New Hampshire-based company said it expects the deal to close on, or around Dec. 3. Proceeds will be used to pay transaction costs, for working capital and general corporate purposes "which may include a return of capital to the company's equity holders The company said its board has approved a share buyback program of up to $500 million. The operator of fitness studios says it had 1,899 outlets in 50 states, the District of Columbia, Puerto Rico, Canada, the Dominican Republic, Panama and Mexico at end September. Shares were down 0.4% Wednesday, but have gained 33% in 2019, while the S&P 500 has gained 24%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

Yahoo BusinessNov 20, 2019
These 3 "Strong Buy" Healthcare Stocks Have 40% Upside — Or More, Says Cowen
The world's population is getting older, rapidly. According to the United Nations, the fastest-growing age group across the world is adults aged 65 and older, with it predicting one out of every six people will be 65 or older by 2050. This means that the age group will make up 16% of the world's total population, 9% higher than it was in 2011, with this figure expected to be larger in North Africa and Europe.To this end, investors are looking for ways to capitalize on the growing opportunity within the healthcare space. In order to pinpoint the most compelling opportunities capable of delivering handsome returns through 2020 and beyond, we turned to the seasoned pros from investing firm Cowen & Co.Using, we were able to get the full scoop on 3 healthcare stocks that the firm's top rated analysts are picking. If it wasn't enough that each has received enough Street Support over the last three months to achieve a "Strong Buy" consensus rating, all of the names boast impressive upside potential. We're talking more than 45% here.BioMarin Pharmaceutical (BMRN) BioMarin is best known for developing innovative therapies to meet the needs of patients with orphan disease, a group of diseases that affects less than 200,000 people in the U.S. The group includes cystic fibrosis, Lou Gehrig's disease, Tourette's syndrome as well as several others.Even though shares have experienced some rockiness year-to-date, 5-star Cowen analyst Phil Nadeau reminds investors that BMR
TrumpChina Apple Kong bill Hong
tradedeal US-China year China report
KongHong bill Trump trade deal
dealtrade Black Friday US-China Best
stocktrade deal Market US-China report
Stockstrade deal US-China report &
Chinatrade US-China deal Trump Kong
HongKong bill Trump trade deal
earningsCall Transcript Q3 Edited conference
AppleTrump Texas billion plant tariffs

Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money Real Estate News Analysis Indicators
Enterprise Application News
Forbes Headlines
Forbes Social Media News - China, Economy & Trade - Financial Markets - Hedge Funds - Telecoms - US
Google Business News
Google Market News
HBS Working Knowledge
INSEAD Knowledge
International Tax Review
L.S. Starrett News
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money Updates: News Digest
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2019 CEOExpress Company LLC